The Effect of a Comprehensive Blood Management Protocol on Decreasing Transfusion Rates Following Primary Total Joint Arthroplasty

Charles A. Hope, II, MD¹, Robert W. Eberle², Constance B. Squibb, RN, BSN, MPA²

(1) Optim Orthopedics, Savannah, GA (2) Medtronic Advanced Energy, LLC, Portsmouth, NH

Presented at the AABB Annual Meeting and CTTXPO 2012 October 6-9, 2012, Boston, MA

Disclosures

- Stryker
 - Consultant and Speaker on Hip and Knee Arthroplasty surgical techniques and instrumentation.
- Medtronic Advanced Energy
 Consultant and Speaker


Blood Management Protocol Hope, et al. AABB Annual Meeting October 6-9, 2012, Boston, MA

INTRODUCTION

- Primary total joint arthroplasty (TJA) is generally an elective procedure and is associated with significant blood loss.
- Considerable variations exists in transfusion practices and in strategies for the management of blood loss from primary TJA which include;
 - Pre-donation of autologous blood
 - Salvage and re-infusion of intraoperative and postoperative shed blood
 - The pre-operative use of erythropoietin for the stimulation of red blood cell production and volume.

Blood Management Protocol Hope, et al.

			Prevalence of Anemia (%)
	Gruson et al (2003)	395	45.6
His and hase	Andrews et al (1997)	100	18
Hip and knee replacements	Myers et al (1991)	27,370	10.8
only	Bonnet et al (1997)	90	41.1
	Haljamae et al (1982)	204	19
	Goodnough et al (1994)	263	25
General ortho	Goodnough et al (1993)	385	30
(hip/knee + other)	Bierbaum (1999)	8561	35
	Halm et al (2004)	550	40.4
Noncardiac	Dunne et al (2002)	6301	33.9
Lung carcinoma	Dougenis et al (2001)	198	24.7
	M'Koma et al (1994)	32	22
Colorectal	Cappell, Goldberg (1992)	315	Dukes A: 39,1 Dukes 8 & C: 56.8 Dukes D: 75.8



Landscape is Changing ...

- Medicare no longer paying for the first three units of blood product
- Headlines are stating,
 "Hospitals are Overspending on Blood Transfusions"
 October 9, 2012 Health Leaders Media
- One report estimates that \$65 M could be saved if readmission after hip and knee replacement were avoided

6 | MDT Confidential

PURPOSE

 The purpose of our study was to evaluate the influence of a comprehensive surgical and clinical blood management protocol on the post-operative transfusion rate in patients undergoing primary TJA.




Blood Management Protocol Hope, et al. AABB Annual Meeting October 6-9, 2012, Boston, MA


MATERIALS AND METHODS


- Study
 - Prospective, continuous series
 - 505 primary TJA procedures
 - Intra- and peri-operative blood management protocol
- Control
 - Retrospective continuous series
 - 1,092 control primary TJA procedures
 - Performed prior to blood management protocol implementation
- Single surgeon
 - Similar MIS/Tissue Sparing surgical techniques and TJR implants

Blood Management Protocol Hope, et al.
















MATERIALS AND METHODS Intra-Operative

The Aquamantys[®] System with Transcollation technology combines radiofrequency (RF) energy and saline for haemostatic sealing and coagulation of soft tissue and bone at the surgical site.



RF energy and saline are applied to tissue

Blood Management Protocol Hope, et al.





e occurs may be occluded, reducing bleeding

AABB Annual Meeting October 6-9, 2012, Boston, MA

Vessels <1mm

RESULTS

- There was no significant difference in demographics
 between study groups.
- Of the 505 treatment TJA cases, there were <u>4 (< 1.0%)</u> cases in which post-operative allogenic blood transfusion was necessary.
- In the control group (n=1,092), there were <u>57 (5.3%)</u> cases requiring allogeneic blood transfusions.
- This proportional difference was statistically significant (p < 0.0001).

Blood Management Protocol Hope, et al. AABB Annual Meeting October 6-9, 2012, Boston, MA

SURGEON RESPONSE

- · In subsequent patients
 - Post-operative reinfusion drains were eliminated for Total Knee Arthroplasty.
 - The use of cell saver and reinfusion drains were eliminated in Total Hip Arthroplasty.

Blood Management Protocol Hope, et al. AABB Annual Meeting October 6-9, 2012, Boston, MA


CONCLUSIONS

 Our findings show a significant decrease in allogeneic transfusion rates following primary TJA when a total intra- and peri-operative blood management protocol was implemented featuring pre-operative anemia control and active intraoperative hemostasis control.



CONCLUSIONS CIDICAL VALUE CONTINUUM OF COMDITIONE Protocols CLINICAL BENEFITS A synthesing intra-operative blood los¹⁴ - May help improve visibility in the surgical field reduced parts preventive cardinations may result in educing and ref the proceedure¹⁴ - Surgificantly reduces parts - Surgificant surgificant - Surgificant surgificant

Blood Management Protoco Hope, et al. AABB Annual Meeting October 6-9, 2012, Boston, MA



Covance report; 2008 MedPAR database based on ICD-9-CM Codes for 100% of Medicare beneficiaries

Blood Management Protocol Hope, et al. AABB Annual Meeting October 6-9, 2012, Boston, MA



- The proposed blood management protocol was easy to implement and effective within the scope of our single surgeon study.
- Further study of this blood management protocol beyond a single surgeon's experience is warranted.





Blood Management Protocol Hope, et al.

Tourniquetless TKA

VUMEDI

January 15, 2013

H. Del Schutte, Jr., M.D. Medical Univ. of South Carolina

MUSC

Disclosure

- Consultant / speaker
- Medtronic
- Stryker
- Depuy

<u>MUSC</u>

Tourniquet Use



Tourniquet Surgery





Tourniquetless tka

Arterial calcification







Tourniquetless tka

• Obesity



Tourniquetless tka

- Infection antibiotic concentration, tissue oxygen perfusion
- Blood loss
- Vascular Effects

 Arterial damage
 - Return to OR
 - DVT
- Multi-organ effects – Pulmonary, hepatic, splenic
- Cognitive function
- Pain
- Muscle function / Rehab



MUSC


Tourniquet use

Antibiotic concentration

• SCIP guidelines

- Vancomycin 1hour
- Ancef 20 min







Tranfusion in TKA

•6 % - 42% incidence
•\$200/unit - \$1000 total cost
•LOS .5 to 1 day longer
•Per surgery costs in pts with transfusions –

*\$3000 knees
*\$2000 hips

•Medical risks - infection
•Decreased supply
•Increased demand MUSC

Picture courtesy Fred Cushner

Tourniquet use

Blood loss

-Blood loss after tka - effect of tourniquet release and cpm - Lotke et al JBJS 1991

- Group 1 full tourniquet and splint
- Group 2 full tourniquet and cpm
- Group 3 tourniquet released and splint -1400cc blood loss
- Group 4 tourniquet released and cpm
 -1800 cc blood loss

MUSC

Hematoma formation





Epinephrine Injection in <u>TKA</u>


- Injected along anticipated arthrotomy site
- · Injected into fat pad



<u>MUSC</u>

Bipolar sealer technology in TKA







Comparison of Blood loss in Total Knee Arthroplasty with and without Tourniquet use: a retrospective study of 372 patients

Schutte Jr HD, Martin SM, Patrick M, Barfield W, Kavolous J.,.

MUSC

Calculated blood loss

172 TKAs with tourniquet	1,499.8
• 113 without tourniquet	1,538.5
• 87 w/o tourniquet and with Transcollation	1,368.5

Transfusion rate			
• 172 TKAs with tourniquet	29%		
• 113 without tourniquet	17%		
• 87 w/o tourniquet and with Transcollation	13%		
	MUS		



Tourniquetless TKA – OR time

Patient group	OR TIME
172 TKAs with tourniquet	62.7
113 without tourniquet	61.5
87 w/o tourniquet and with Transcollation	55.9

<u>Tourniquetless TKA – COST</u>

Cost reductions in our series based on:

- No tourniquet
- No drain
- 6 minutes OR time

MUSC



Tourniquet use

- Arterial damage

 Often missed at surgery
 - -.1% primary tka
 - -.2% revision tka
 - 50% lawsuit





Tourniquet use

- Arterial damage
- Return to OR
 - -Missed arterial injury

-Hematomas





Tourniquet use – DVT?

- PTE was detected in 6 patients (7.0%)
- 2 of 5 (40.0%) patients bilateral TKAs w T
- 3 of 42 (7.1%)bilateral TKAs w/o T
- 1 of 14 (7.1%) unilateral TKA w T
- PTE did not occur in patients who underwent unilateral TKA without tourniquet.
- median D-Dimer significantly higher in patients with tourniquet, both in unilateral TKA (p=0.003) and in bilateral TKAs (p=0.004).

Nishiguchia, et al 2005

MUSC

Tourniquet use

- Pulmonary function
- Multi-organ function



Tourniquet release



MUSC

C

Tourniquet use

Pulmonary function

"Tourniquet application within a safe limit may cause pulmonary gas exchange impairment several hours after tourniquet deflation"

Chevening, 2019 Jun 133(b) doi:10.312091477447.20190426-15. Pulmonary gas exchange impairment following tourniquet deflation: a prospective, single-blind clin tint. Lin L. Wang L. Bai Y. Zheng L. Zhao X. Xong X. Jun L. XW. Wang W. Areath Arang, 2019 Aug 111(2):598-43. Eps 2019 Jul 7. Ischemic preconditioning attenuates pulmonary dysfunction after unilateral thigh tourniquet-induc ischemic areportusion. Lin LV. Wang L. Wang W. Jun L. Zhao X. Zheng D. Jun D. Jang LW. Wong XO.

Tourniquet use

Multi-organ function

Am J Surg. 1992 Sep;164(3):248-53.

Liver and spleen phagocytic depression after peripheral ischemia and reperfusion. Thompson PN, Cho E, Blumenstock FA, Shah DM, Saba TM.


Department of Physiology and Cell Biology, Albany Medical College, Union University, New York 12208.



<u>Tourniquet use</u> • Cardiac function

J Int Med Res. 2010 Jul-Aug;38(4):1519-29. Effect of high-dose vitamin C on oxygen free radical production and myocardial enzyme after tourniquet ischaemia-reperfusion injury during bilateral total knee replacement Lee JY Kim CJ Chung MY





Tourniquet use

Cognitive function

Cognitive dysfunction after tka Rodriguez et al, Jl. of Arthroplasty 2005 HITS (cerebral emboli) 22 of 37 pts. Cognitive dysfunction 41% at 1 week 18% at 3 mos. higher complication rate

SURGERY



Tourniquet use

• Pain

- Vandenbussche et al, International Orthopedics
- Prospective randomized study with and without tourniquet Sig. decreased pain at 6 hours
- Increased flexion at 5 daysAbdel-Salam, JBJS 77-B
 - 80 pts. sig. degcreased pain without tourniquet
- Barwell, JBJS 79-B - 88 pts. Sig. decreased pain with early release
- Worland, Jl of Arthroplasty 1997
 28 bilat knees, sig. decreased pain without tournique MUSC

<u>Tourniquet use</u> • Muscle function



Tourniquet use

Patellofemoral tracking

-Husted, Jl. of Arthroplasty 2005

• Tourniquet deflation improved patellar tracking

-Lombardi, JBJS-B 87-B

• Decreased need for lat. release if tourniquet released

MUSC

Tourniquet use

Muscle function

Arthroscopy. 2001 Jul;17(6):603-7.

The effect on leg strength of tourniquet use during anterior cruciate ligament reconstruction: A prospective randomized study.

Nicholas SI Tyler TF McHugh MP Gleim GW

CONCLUSIONS: Tourniquet use of less than 114 minutes during ACL reconstruction had no effect on the strength of the lower extremity after surgery.

MUSC

Tourniquet Use

- Range of Motion
- Ledin, Aspenberg, and Good. Acta Orthopaedica 2012; 83 (5): 499–503 499
 - Randomized RSA study with 50 patients
 - Found less postoperative pain and greater range of motion $(11^{\circ} \text{ more})$ in the non-tourniquet group (p = 0.001 at 2 years).

Range of Motion



Range of Motion



MUSC

Tourniquet Use

- Cement Interdigitation
- Ledin, Aspenberg, and Good. Acta Orthopaedica 2012; 83 (5): 499–503 499

No statistically significant effect on prosthesis migration

- Vertullo CJ. Presented at the Australian Knee Society Annual Scientific Meeting 2009, Palm Cove; AOA Annual Science Meeting 2010, Adelaide; ISAKOS Meeting 2011, Rio De Janeiro.
 - Prospective, randomized trial of 40 patients, quantified cement penetration in tourniquet and tourniquetless arms.
 - Mean cement penetration and standard deviation (SD) were nearly identical in each group (2.98 mm with SD of 0.82 in the tourniquet group versus 3.10 with SD of 0.84 in the tourniquetless group).

Tourniquetless TKA - Rehab

• Our series of 372 patients

Patient group	ROM at 8wks
172 TKAs w/ tourniquet	105.4
113 w/o tourniquet	109.5
87 w/o tourniquet and with Transcollation	n <u>114.6</u>

MUSC

CMS - Applicable Conditions

- The FY 2012 final rule addressed the following applicable readmissions:
 - 1. Acute myocardial infarction
 - 2. Heart failure
 - 3. Pneumonia

Readmission for orthopaedic procedures is NOT currently covered; this may change...

MUSC

(

Unplanned Readmissions after TKA <u>- Poster #20 AAHKS 2012</u>

Consideration	Metric
30 Day Readmission Rate	5.65%
Readmission associated with:	
Increased LOS	p < .001
Revision surgery	p < .001
Most common readmitting diagnoses:	
Post-op infection	.5% of pts
Unspecified prosthetic complication	.31% of pts
Hematoma	.28% of pts
PE	.22% of pts
Financial Impact:	
Avg profit-w/ reimbursement	\$5,219
Re-admitted pts - w/ reimbursement	\$2,583 less profitable (p=.001)
Net avg loss - w/o reimbursement	\$5,326 per episode of care

Relationship between timing of <u>TQ release and readmission</u>

Rama et al, J Bone Joint Surg, 2007				
Parameter	Early-TQ Release	Late-TQ Release	P Value	
All regional complications	7.9%	14.8%	.006	
Complications that required another operation*	.3%	3.1%	.04	

*Wound dehiscence, hematomas, and infections that required drainage and / or debridement and knee stiffness that required manipulation with pt under anesthesia

10x rate of reoperations due to post op complications in late versus early TQ release group!

MUSC

Tourniquetless TKA

- Infection antibiotic concentration, tissue oxygen perfusion
- Blood loss
- Vascular Effects

 Arterial damage
 Return to OR
 - DVT
- Multi-organ effects
 Pulmonary, hepatic, splenic
- Cognitive function
- Pain
- Muscle function / Rehab



MUSC

Tourniquetless TKA

- Intraoperative (real time) control of blood loss
- Decreased metabolic challenges
- Improved postoperative function





Thank you